AstraZeneca PLC

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:26 2024-05-10 am EDT			5-day change	1st Jan Change
12,370 ^GBX	+0.31%		+2.66%	+16.70%

May. 08	AstraZeneca, Merck Sue to Protect Lynparza Cancer Drug Patents	MT
May. 08	AstraZeneca, Merck Sue to Protect Lynparza Cancer Drug Patents	MT

AstraZeneca : Imfinzi and tremelimumab with chemotherapy demonstrated overall survival benefit in POSEIDON trial for 1st-line Stage IV non-small cell lung cancer

May 07, 2021 at 02:05 am EDT

First Phase III trial to demonstrate overall survival benefit with tremelimumab

Imfinzi plus chemotherapy demonstrated progression-free survival benefit, but a trend in overall survival did not achieve statistical significance

Attachments

Original document
Permalink

Disclaimer

AstraZeneca plc published this content on 07 May 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 07 May 2021 06:04:02 UTC.

Latest news about AstraZeneca PLC

AstraZeneca, Merck Sue to Protect Lynparza Cancer Drug Patents	May. 08	MT
AstraZeneca, Merck Sue to Protect Lynparza Cancer Drug Patents	May. 08	MT
AstraZeneca, Merck Sue Over Alleged Cancer Drug Patents Infringement	May. 08	MT
AstraZeneca, Merck Sue Over Cancer Drug Patent Infringement	May. 08	MT
AstraZeneca to Reportedly Withdraw COVID-19 Vaccine Amid Cooling Demand	May. 08	MT
SERUM INSTITUTE OF INDIA ON ASTRAZENECA'S WITHDRAWAL OF VAXZERVR…	May. 08	RE
Jefferies Lifts AstraZeneca PT, Maintains Hold Rating	May. 08	MT
ASTRAZENECA : Jefferies sticks Neutral	May. 08	ZD
AstraZeneca says withdraws Covid vaccine "for commercial reasons"	May. 08	AN
UBS raises Centrica to 'buy' from 'neutral	May. 08	AN
AstraZeneca lifts FTSE 100 to record high; BOE rate decision on tap	May. 08	RE
AstraZeneca to Remove COVID-19 Jab from EU Markets Due to Commercial Reasons	May. 07	MT
AstraZeneca to withdraw COVID-19 vaccine globally, Telegraph reports	May. 07	RE
AstraZeneca to withdraw Covid vaccine worldwide, The Telegraph reports	May. 07	RE
The Oxford-Astrazeneca COVID Vaccine Is Being Withdrawn Worldwide- The Telegraph	May. 07	RE
THE OXFORD-ASTRAZENECA COVID VACCINE IS BEING WITHDRAWN WORL…	May. 07	RE
Berenberg Raises AstraZeneca PT, Keeps Rating at Buy	May. 07	MT
ASTRAZENECA : Berenberg keeps its Buy rating	May. 07	ZD
AstraZeneca target raised; Antofagasta lowered	May. 07	AN
BP starts USD1.75 billion share buyback scheme	May. 07	AN
Cellectis: alliance with AstraZeneca finalized	May. 06	CF
Cellectis Secures $140 Million Additional Equity Investment From AstraZeneca	May. 06	MT
AstraZeneca: equity investment in Cellectis	May. 06	CF
AstraZeneca completes collaboration and investment deal with Cellectis	May. 06	AN
AstraZeneca Secures 44% Stake in French Biotech Cellectis	May. 06	MT

Chart AstraZeneca PLC

Duration

Period

More charts

Company Profile

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Sector

Pharmaceuticals

Calendar

2024-05-19 - American Thoracic Society Conference - Abstarct Number - P297

Related indices

STOXX EUROPE 600 (EUR) , FTSE 100

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

ASTRAZENECA : Strong Q1 raises hopes of a guidance upgrade

April 25, 2024 at 12:02 pm EDT

More Strategies

Ratings for AstraZeneca PLC

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

154.8 USD

Average target price

166.5 USD

Spread / Average Target

+7.53%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ASTRAZENECA PLC	+16.70%	240B
ELI LILLY AND COMPANY	+30.38%	684B
NOVO NORDISK A/S	+26.51%	568B
JOHNSON & JOHNSON	-4.36%	361B
MERCK & CO., INC.	+19.30%	329B
ABBVIE INC.	+3.73%	284B
NOVARTIS AG	+8.78%	208B
ROCHE HOLDING AG	-7.93%	200B
AMGEN INC.	+7.68%	166B
PFIZER, INC.	-2.71%	159B

Other Pharmaceuticals

AstraZeneca PLC

Equities

AZN

GB0009895292

Pharmaceuticals

AstraZeneca : Imfinzi and tremelimumab with chemotherapy demonstrated overall survival benefit in POSEIDON trial for 1st-line Stage IV non-small cell lung cancer

EPS Revisions